Theranib Inc. announces the publication of its US patent on January 9, 2025, securing protection for VE3, a groundbreaking ALDH1A3-targeted cancer therapy.
ALDH1A3 and Breast Cancer Progression
Explore the pivotal role of ALDH1A3 in breast cancer progression highlighted in a recent study, reinforcing Theranib’s mission to advance ALDH1A3-targeted therapies.
The Expanding Role of ALDH1A3 in Cancer
Discover the expanding role of ALDH1A3 in cancer stem cells and its therapeutic potential, reinforcing Theranib’s focus on precision-targeted cancer therapies.